Drug Profile
Research programme: second-generation long-acting PDE5 inhibitors - Pfizer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Erectile dysfunction; Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in United Kingdom (PO)
- 21 Aug 2008 Preclinical trials in Hypertension in United Kingdom (PO)